Tscan Therapeutics (NASDAQ:TCRX) is a biotechnology firm focused on the innovation and development of T-cell receptor (TCR)-engineered T cell therapies for the treatment of patients with cancer. Its operations are mainly centered around the research, development, and commercialization of its proprietary TCR-T cell therapy platform, which aims to identify and harness the power of immune cells to fight cancer more effectively. The company's projects include a diverse pipeline of TCR-T therapies targeting both solid tumors and hematologic malignancies. Objectives of Tscan Therapeutics are to advance these therapies through clinical trials, achieve regulatory approvals, and ultimately, deliver new and effective cancer treatments to patients in need.